Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
By Adria Calatayud
Roche Holding expects drugs it already has on the market and a trio of medicines due to be launched shortly to deliver sales growth for its pharmaceutical business through the end of the decade, its chief executive said.
The Swiss drugmaker's on-market pharma portfolio, together with its Gazyva drug for lupus, giredestrant for breast cancer and fenebrutinib for multiple sclerosis, should make up for any hit from generic competition until 2030, Roche Chief Executive Thomas Schinecker said at an event with investors in London on Tuesday.
The company in September said it expected its on-market pharma portfolio to deliver growth until 2028 and be stable thereafter.
"We will no longer have a situation, even with what we have in hand, where we are not going to grow," Schinecker said. "We will continue our good growth momentum not only until the end of the year, the end of the decade, but beyond."
The contribution from drug candidates in Roche's late-stage pipeline for which the company expects to release study results over the next three years will come on top, he said.
Roche's diagnostics division is expected to deliver sales growth in the mid-to-high single digit percentage range over the long term, Schinecker said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
May 12, 2026 09:21 ET (13:21 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States